New Biomarker Could Detect Alzheimer’s Years Before Symptoms Appear
TSPO, a major marker of brain inflammation, may offer a way to detect Alzheimer’s disease long before memory problems and other symptoms develop. Findings published in Acta Neuropathologica suggest it could transform both diagnosis and treatment strategies.
“This is the first study to really examine how early this biomarker increases and where it begins rising in the brain,” said Tomás R. Guilarte, lead researcher and dean of FIU’s Robert Stempel College of Public Health & Social Work. “If we can use this information to help delay Alzheimer’s progression by even five years, it can drastically improve patients’ lives and reduce disease prevalence.”
Longstanding research on TSPO
Guilarte, a recognized authority on TSPO (translocator protein 18 kDa), has investigated the protein for more than 30 years. His research helped establish it as a dependable imaging marker for identifying neuroinflammation across multiple neurological, neurodegenerative, and psychiatric conditions.
For the current study, Guilarte and colleagues applied advanced imaging techniques to track TSPO activity in genetically engineered mouse models of familial Alzheimer’s. They then validated these results using donated brain tissue from members of the world’s largest community with early-onset familial Alzheimer’s, based in Antioquia, Colombia.
These families carry the “paisa” mutation, first identified by the late Dr. Francisco Lopera, a co-author of the study who spent his career searching for ways to prevent Alzheimer’s. Individuals with this genetic variant often develop symptoms in their 30s or 40s and typically die in their 50s.
